Halozyme Therapeutics, Inc. $HALO Shares Acquired by Osaic Holdings Inc.

Osaic Holdings Inc. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 80.9% during the 2nd quarter, Holdings Channel.com reports. The fund owned 53,448 shares of the biopharmaceutical company’s stock after buying an additional 23,910 shares during the period. Osaic Holdings Inc.’s holdings in Halozyme Therapeutics were worth $2,972,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. DLD Asset Management LP acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at approximately $650,250,000. Alliancebernstein L.P. lifted its stake in Halozyme Therapeutics by 4.8% in the first quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock valued at $205,156,000 after buying an additional 146,677 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Halozyme Therapeutics by 127.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after acquiring an additional 1,425,674 shares during the period. LSV Asset Management grew its position in shares of Halozyme Therapeutics by 40.2% during the second quarter. LSV Asset Management now owns 1,255,240 shares of the biopharmaceutical company’s stock worth $65,298,000 after acquiring an additional 360,049 shares during the last quarter. Finally, Royal London Asset Management Ltd. grew its position in shares of Halozyme Therapeutics by 122.3% during the second quarter. Royal London Asset Management Ltd. now owns 1,101,912 shares of the biopharmaceutical company’s stock worth $57,321,000 after acquiring an additional 606,236 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $68.87 on Friday. The company has a 50-day moving average of $67.34 and a two-hundred day moving average of $65.41. The stock has a market cap of $8.10 billion, a price-to-earnings ratio of 14.50, a PEG ratio of 0.37 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.59 and a quick ratio of 1.37. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same quarter in the prior year, the firm earned $1.27 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HALO. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Leerink Partners raised shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective on the stock in a research note on Tuesday, October 14th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $75.10.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00. Following the transaction, the director directly owned 42,952 shares in the company, valued at $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $55,285,726.65. This represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 85,661 shares of company stock worth $6,036,837 in the last 90 days. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.